RxDoctor Payments Data

Seema Bir, MD

Family Medicine · Rancho Mirage, CANPI 1720099294

Payments from drug & device makers

$5,108in general payments, 2019–2025

Across 280 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$684
  • GSK$558
  • Lilly USA, LLC$348
  • Johnson & Johnson$328
  • Pfizer$274
  • Amarin Pharma, Inc.$264
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,108100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,108 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$822,578
Medicare patients
611
Services billed
15,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide125$145,225
EliquisApixaban122$111,286
MounjaroTirzepatide69$92,709
JanuviaSitagliptin Phosphate44$57,523
FarxigaDapagliflozin Propanediol45$50,215
JardianceEmpagliflozin36$46,188
XifaxanRifaximin15$34,522
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$30,253
EntrestoSacubitril/Valsartan22$30,133
ProliaDenosumab16$28,183
TrulicityDulaglutide13$14,613
XareltoRivaroxaban15$13,986
MyrbetriqMirabegron15$13,026
Repatha SureclickEvolocumab11$12,948
Lantus SolostarInsulin Glargine,hum.Rec.Anlog96$11,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$147$145,225125 claims
PfizerEliquis, Premarin, Paxlovid$274$123,158162 claims
Lilly USA, LLCMounjaro, Trulicity$348$107,32382 claims
MerckJanuvia$47$57,52344 claims
AstraZenecaFarxiga$237$50,21545 claims
Boehringer IngelheimJardiance$225$46,18836 claims
GSKTrelegy Ellipta, Anoro Ellipta$558$39,13655 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$80$34,52215 claims
NovartisEntresto$165$30,13322 claims
AmgenProlia$684$28,18316 claims
Johnson & JohnsonXarelto$328$13,98615 claims
Astellas Pharma US IncMyrbetriq$74$13,02615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →